The aim of this study was to determine if bone marrow mononuclear cell (BMMC) transplantation is safe for moderate to severe idiopathic dilated cardiomyopathy (IDC). Clinical trials have shown that this procedure is safe and effective for ischemic patients, but little information is available regarding non-ischemic patients. Twenty-four patients with IDC, optimized therapy, age 46 ± 11.6 years, 17 males, NYHA classes II-IV, and left ventricular ejection fraction <35% were enrolled in the study. Clinical evaluation at baseline and 6 months after stem cell therapy to assess heart function included echocardiogram, magnetic resonance imaging, cardiopulmonary test, Minnesota Quality of Life Questionnaire, and NYHA classification. After cell transplantation 1 patient showed a transient increase in enzyme levels and 2 patients presented arrhythmias that were reversed within 72 h. Four patients died during follow-up, between 6 and 12 weeks after therapy. Clinical evaluation showed improvement in most patients as reflected by statistically significant decreases in Minnesota Quality of Life Questionnaire (63 ± 17.9 baseline vs 28.8 ± 16.75 at 6 months) and in class III-IV NYHA patients (18/24 baseline vs 2/20 at 6 months). Cardiopulmonary exercise tests demonstrated increased peak oxygen consumption (12.2 ± 2.4 at baseline vs 15.8 ± 7.1 mL·kg -1 ·min -1 at 6 months) and walked distance (377.2 ± 85.4 vs 444.1 ± 77.9 m at 6 months) in the 6-min walk test, which was not accompanied by increased left ventricular ejection fraction. Our findings indicate that BMMC therapy in IDC patients with severe ventricular dysfunction is feasible and that larger, randomized and placebo-controlled trials are warranted.
Introduction
Dilated cardiomyopathy is the most common form of non-ischemic cardiomyopathy, characterized by ventricular dilatation, cardiomyocyte death, thinning of chamber walls, and fibrosis (1) (2) (3) . Despite optimized pharmacological therapy, patients with dilated cardiomyopathy frequently progress to end-stage heart failure. For these patients, the only available therapy is heart transplantation, which is limited to a very small number of patients. Therefore, new therapeutic options for these patients are urgently needed.
In preclinical models, cardiovascular stem cell therapy has been used successfully in a variety of cardiac diseases,
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2 including dilated cardiomyopathy (4) (5) (6) (7) (8) (9) . In the clinical setting, cell therapies have been previously used in patients with ischemic heart disease, both in the acute and chronic stages. In most trials, the mononuclear fraction of bone marrow has been used, but a variety of cell types from bone marrow and skeletal myoblasts have also been delivered to patients (10) (11) (12) (13) (14) (15) (16) (17) . Results have demonstrated excellent safety with encouraging signs of clinical improvement (10) (11) (12) (14) (15) (16) (17) . Very few studies have applied cell therapy to patients with non-ischemic dilated cardiomyopathy (18) (19) (20) (21) , and conflicting results as to the safety of the procedure have been reported.
Based on these findings and given the limited therapeutic options for refractory dilated cardiomyopathy, we decided to perform a phase I clinical trial using bone marrow mononuclear cells (BMMC) in idiopathic dilated cardiomyopathy patients with functional classes II-IV of the New York Heart Association (NYHA).
Material and Methods

Patients
From February 2005 through August 2006 we enrolled 24 patients with optimized therapy and a diagnosis of idiopathic dilated cardiomyopathy (IDC) according to World Health Organization criteria. Inclusion criteria required left ventricular ejection fraction (LVEF) (Simpson) <35%, peak oxygen consumption (VO 2 peak ) <16 mL·kg -1 ·min -1 , functional classes II-IV of NYHA, signed informed consent, and ages between 18 and 70 years. Exclusion criteria were: coronary artery disease based on coronary angiography prior to cell delivery, dilated cardiopathies of ischemic or chagasic origin, primary valve disease, excessive use of alcohol or illicit drugs, pregnancy, ventricular arrhythmias, and any co-morbidity with impact on survival. The study complied with Declaration of Helsinki regulations (1975), reviewed in Edinburg (2000). The Ethics Review Board of the National Cardiology Institute approved the protocol that was registered by the National Ethics Committee (CONEP -registration No. 9287). The study was also registered in ClinicalTrials.gov (registration No. NCT00612911).
Study design
Patients underwent the following exams at baseline and 6 months after cell therapy: chest X-ray, blood biochemistry, 12-lead electrocardiogram (ECG) and 24-h Holter, echocardiography, B-type natriuretic peptide (BNP, Biosite Inc., USA), cardiopulmonary exercise testing (CPET), magnetic resonance imaging (MRI), 6-min walk test, NYHA classification, and Minnesota Quality of Life Questionnaire. Patients were followed for 6 months after cell therapy at the outpatient clinic for cardiomyopathy of the National Cardiology Institute. The safety endpoints were any complications related to the cell injection procedure including levels of cardiac enzyme (troponin t), ventricular arrhythmias, conduction disturbances, and death by any cause. Patients underwent bone marrow aspiration (80-100 mL from the iliac crest) under sedation and local anesthesia. BMMC were obtained after Ficoll gradient centrifugation. After extensive washing in saline with autologous serum, cells were diluted in 20 mL saline containing 5% autologous serum and were slowly delivered to the coronary arteries by cardiac catheterization (10 mL in the left anterior descending artery, 5 mL in the circumflex artery and 5 mL in the right coronary). The aspiration and cell preparation procedure lasted 2 to 2.5 h. Intracoronary cell delivery was performed right after cell preparation and the time spent in the catheterization laboratory was approximately 1 h, after which patients were taken to the Intensive Care Unit for 24 h with continuous monitoring of ECG and periodic measurements of enzyme levels. Patients remained hospitalized for a total of 72 h and were then discharged for home. A portion of the cell suspension was used for the determination of percent CD34 + cells in the mononuclear fraction using the ISHAGE protocol (22) and a FACS-Canto instrument (BD Biosciences, USA).
Echocardiography
Echocardiographic studies were conducted according to the American Society of Echocardiography. Global LVEF was calculated from measurements of left ventricular end diastolic and end systolic volumes in apical 4 and 2 chamber views using Simpson's rule and a Vivid 7 echocardiograph (GE Healthcare, UK).
Cardiopulmonary exercise testing
CPET was performed using a treadmill ramp protocol. Patients were encouraged to exercise until exhaustion or when limited symptoms were detected. Standard 12-lead electrocardiograms were obtained at rest, each minute during exercise, and for at least 5 min during the recovery phase. Blood pressure was measured with a standard sphygmomanometer. VO 2 peak was defined as the highest VO 2 observed during the last minute of exercise. Minute ventilation (VE), oxygen uptake (VO 2 ) and carbon dioxide output (VCO 2 ) were analyzed at rest and every 20 s with a VO 2000 analyzer (MedGraphics, USA). VE and VCO 2 values were used to calculate the VE/VCO 2 slope via least squares linear regression.
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Magnetic resonance imaging MRI was performed using a 1.5T EXCITE ® HD instrument (GE Healthcare). Left ventricle volumes and LVEF were calculated using the GE Software (Mass Analysis Plus V4.0.1 for Advantage Windows 4.0, and Report Card 3.0, for ADW 4.3). Short and long axis cine views were acquired throughout the entire volume of the left ventricle. The short axis views were used for the volume and LVEF calculations. Typically the short axis slices were 8-mm thick, with a 2-mm gap.
Statistical analysis
Data were analyzed using the R software version 2.6.1 (23) . We used the Shapiro test to determine if normal distribution was applicable to the variables. Normally distributed continuous variables are reported as means ± SD. When distribution was not normal, the median and inter-quartile interval were used to present the data. Because we were interested in measuring differences between baseline and each time, data from patients who died during follow-up were excluded from the analysis. Due to the small number of patients, longitudinal comparison of continuous variables was performed by the paired Student t or Wilcoxon test but P values for the analysis were adjusted by the Bonferroni post-test. Categorical variables were evaluated by the Fisher exact test. We considered 95% as the confidence level.
Results
Cell characterization
From 80-100 mL of marrow aspirate we obtained 177 ± 125 million (range of 58 to 620 million) mononuclear cells with 98 ± 1.12% viability (Trypan exclusion). All cells, except for a small aliquot used for cytometry, were injected in the patients. Flow cytometry analysis (BD Facs-Canto) showed that the injected mononuclear fraction contained a mean of 1.3 ± 0.7% CD34 + cells (ISHAGE Protocol).
Baseline characteristics of the patients
Key demographic characteristics of the 24 patients are listed in Table 1 . Optimized pharmacological therapy included β-blockers, angiotensin-converting enzyme inhibitors and diuretics before enrollment, and was kept throughout the end of the study except for necessary adjustments of diuretic doses.
Safety evaluation
During the cell injection procedure one patient developed a transient right bundle branch blockage (RBBB), one patient had atrial fibrillation (AF) that was reversed with amiodarone within 8 h, and one patient showed an elevation in troponin I enzyme levels from 0.5 to 3.3 12 h after cell injection, without pain, ECG or hemodynamic instability that normalized within 72 h. No other patient had an increase in cardiac enzymes.
Four patients died during the 6-month follow-up. The deaths occurred on the 48th, 52nd, 57th, and 86th day after cell injection. One patient died of sepsis during hospitalization for digitalis intoxication. Two other deaths were caused by acute cardiogenic pulmonary edema and cardiogenic shock, respectively. All 3 deaths were thus considered to be unrelated to the procedure. The cause for the last death was undetermined. The patient died at home in his sleep, and arrhythmias related to cell injection leading to sudden cardiac death could not be ruled out. Unfortunately, no autopsies were authorized by the families.
Clinical evaluation
There were no significant differences in mean weight, arterial pressure, heart rate, or blood biochemistry including hemoglobin, sodium, potassium, creatinine, and albumin levels during the course of the study. ECGs performed during the 72 h of patient hospitalization for the procedure revealed no alterations other than those described in the above safety evaluation (one AF and one RBBB). The number of ventricular ectopic beats detected during the 24-h Holter monitoring was not significantly different at baseline LVEF determined by the echocardiogram using Simpson's rule is illustrated in Figure 1A . There was no significant variation after cell injection (23.8 ± 5.3 at baseline vs 25.0 ± 7.7 at 6 months). The insets show individual values for LVEF during follow-up. MRI analyses showed that neither LVEF (Figures 1B; 19 .6 ± 5.9 at baseline vs 20.2 ± 9.6 at 6 months) nor mean systolic (287.7 ± 94.1 at baseline vs 297.7 ± 120.2 at 6 months) or diastolic (355.7 ± 108.4 at baseline vs 368.0 ± 138.2 at 6 months) diameters changed significantly during the 6-month follow-up.
Mean BNP levels showed a significant decrease 2 months after cell therapy, decreasing from 410.6 pg/mL at base-
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4 line to 317.4 pg/mL (P < 0.001). This decrease was not sustained at 6 months when BNP levels reached 326 pg/mL (P = 0.07 vs baseline). CPET analysis revealed that maximal oxygen consumption increased significantly compared to baseline after cell therapy. Figure 2A shows variation in maximal oxygen consumption, with mean values increasing from 12.2 ± 2.41 mL·kg -1 ·min -1 at baseline to 15.8 ± 7.1 mL·kg -1 ·min -1 at 6 months after cell therapy. Figure 2B shows the percentage of patients with VO 2 peak below 14 mL·kg -1 ·min -1 (threshold for cardiac transplantation) at baseline and 6 months (P = 0.03) after cell therapy. Exercise duration normalized to the values obtained at baseline also showed a significant gain after cell therapy (29.2% at 2 months and 51.0% at 6 months, P = 0.003 and P = 0.01). The six-minute walk test showed improvement in mean values ranging from 377.2 ± 85.4 m at baseline to 441.1 ± 85.3 m at 2 months (P = 0.03), and 444.1 ± 77.9 m at 6 months (P = 0.01; Figure 2C) .
Patients also had a significant improvement in NYHA class ( Figure 3A ) and quality of life measured by the Minnesota Questionnaire (P = 0.005) following cell therapy (63 ± 17.9 at baseline vs 28.8 ± 16.7 at 6 months; Figure 3B ). While at baseline the majority of patients (14) were in classes III and IV, after therapy 13 of the 20 patients were in class I ( Figure  3A ; P < 0.001).
Discussion
Safety reports for cell therapy in dilated cardiomyopathy are contradictory. No adverse events have been reported in a trial where mononuclear cells were delivered to the coronary arteries in 24 patients after coronary sinus occlusion (19) . Another trial used the intramyocardial route to deliver cells during thoracotomy, but only 5 IDC patients were included in the trial that reported 7 episodes of ventricular fibrillation during the procedure and 2 deaths by the same mechanism during the perioperative period (18) . A third trial was interrupted for safety reasons after performing mononuclear cell injection by catheterization with balloon inflation in two patients (20) . However, Fischer-Rasokat et al. (21) recently reported intracoronary delivery of cells using balloon inflation in 33 patients to be safe.
The present study indicates that intracoronary delivery of autologous mononuclear cells from bone marrow is safe and feasible in the IDC setting. Two of the three adverse events observed in the 24 patients involved atrial fibrillation and a transient right bundle branch block. The third event, an increase in troponin I levels, may have been directly associated with cell delivery but the patient was asymptomatic and hemodynamically stable without ECG changes. At any rate, this should lead to increased caution during the procedure.
Although there was considerable variability in ectopic beats during all phases of the study, including baseline, we did not observe an increase in ventricular or supra-ventricular ectopic beats during Holter monitoring after cell therapy. This confirms reported literature results indicating that intracoronary injection of bone marrow-derived cells is not arrhythmogenic (11, (14) (15) (16) 24) .
The number of deaths observed during the 6-month follow-up of this study (4 of the 24 patients) is compatible with the disease state presented by the patients, since mean ejection fraction was below 25% as determined by ECG and 20% by MRI (25) . Furthermore, Seth et al. (19) have reported identical mortality in a cell therapy trial for patients with non-ischemic dilated cardiomyopathy. Considering the time interval between the procedure and the occurrence of deaths by pulmonary edema and cardiogenic shock, the severity of the heart failure of the patients at enrollment and the natural history of the disease, we consider these deaths most likely not to be related to the cell injection procedure. As for the patient who died at home, arrhythmias related to cell injection leading to sudden cardiac death cannot be ruled out. Unfortunately, no autopsies were authorized by the families.
The study was not designed to test for efficacy, but functional and life quality parameters were evaluated at 2 and 6 months after cell therapy. Cardiac function, as determined by ECG and MRI showed no improvement in mean ejection fraction. This is in contrast to the results reported by Seth et al. (19) and Fischer-Rasokat et al. (21) , who detected a significant increase in ejection fraction (EF) after cell therapy. Seth at al. (19) found, by ECG, an increase of 5.4% in EF% after 6 months in 24 patients who had received cell therapy. Fischer-Rasokat et al. (21) reported a 3.2% increase in LVEF by ventriculography 3 months after cell delivery. A small percentage of the patients in our study (26%) also showed improvement of 5% or more in EF% 6 months after cell therapy. Furthermore, in both Seth's and Fischer-Rasokat's studies some of the patients showed no improvement in EF%. This variability in individual response to therapy raises the question about which variables could influence cell therapy outcome. In the small population studied here we were not able to correlate improvement in LVEF to any other variable that might be relevant for the outcome of this therapy, such as age, gender, number of injected cells, percentage of CD34 + cells or baseline LVEF, using a univariate model. Colony-forming assays of the injected cells were not performed and therefore we could not correlate this variable to regional contractile function as done by Fischer-Rasokat et al. (21) .
The cardiopulmonary evaluation of the patients using CPET showed significant improvement after cell therapy in Especially important was the reduction of the number of patients with maximal oxygen consumption below the threshold for cardiac transplantation (14 mL·kg -1 ·min -1 ), which declined from 75% at baseline to 36.8% 6 months after cell therapy. Even if we consider the more strict recommendation of VO 2 peak below 12 mL·kg -1 ·min -1 for the indication of heart transplantation in patients under β-blocker therapy (the majority of our patients), cell therapy still reduced the number of patients with VO 2 peak below this threshold at baseline from 50% (10 of 20 patients) to 25% (5 of 20 patients) 6 months after cell delivery.
In agreement with the increase in cardiopulmonary function, more qualitative parameters such as NYHA classification and Minnesota Quality of Life questionnaire showed significant improvements after cell therapy.
Cell therapy using bone marrow-derived cells has been successfully applied to the treatment of acute and chronic ischemic heart disease (15, 16, 26) . Since the pioneering work of Strauer et al. (27) , many groups have performed phase I/II trials showing the intracoronary delivery of autologous marrow cells to be safe and potentially effective (16, 26, 27) . Larger randomized trials have confirmed the efficacy of this new therapy (28) (29) (30) , although these results have been disputed (31) . The beneficial effects of cell therapy in the setting of ischemic heart disease are not fully understood, and proposed mechanisms of action have included new myocyte formation, angiogenesis and secretion of trophic and anti-apoptotic factors by the mononuclear cell fraction of bone marrow (17, 32) . The capacity of bone marrow cells to regenerate myocytes has been a matter of intense debate (7, 17, (32) (33) (34) (35) (36) . This safety trial indicates a broad variability in results for individual patients. Certainly a better understanding of the mechanisms of action will improve our capacity to apply bone marrow-derived cell therapies to patients with dilated cardiomyopathy. In conclusion, our findings agree with published results, showing that cell therapy is safe and feasible, also in the setting of dilated cardiomyopathy. Larger, randomized, double-blind and placebo-controlled trials are necessary to test for efficacy and the present study laid the groundwork for such a trial, which we are currently performing (NCT 00333827). 
